0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Growth Hormone Replacement in Healthy Older Men Improves Body Composition but Not Functional Ability

Maxine A. Papadakis, MD; Deborah Grady, MD, MPH; Dennis Black, PhD; Mary Jo Tierney, RN, MS; Gretchen A.W. Gooding, MD; Morris Schambelan, MD; and Carl Grunfeld, MD, PhD
[+] Article and Author Information

From the University of California, San Francisco; the Department of Veterans Affairs Medical Center; and San Francisco General Hospital, San Francisco, California. Acknowledgments: The authors thank Margaret Kagawa, RN, MS, Lauren Wells, PT, MS, Daniel Stryer, MD, Esther Carlton, Peter Hadreas, PhD, and Sylvia Miles for their contributions to this project. Grant Support: By the Department of Veterans Affairs Merit Review Program; grants NIH-DK40990, DK45833, and M01RR00083; Genentech, Inc.; and the Nichols Institute. Requests for Reprints: Maxine A. Papadakis, MD, Department of Veterans Affairs Medical Center, 4150 Clement Street 111A1, San Francisco, CA 94121. Current Author Addresses: Drs. Papadakis, Grady, Gooding, and Grunfeld and Ms. Tierney: Department of Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA 94121.


Ann Intern Med. 1996;124(8):708-716. doi:10.7326/0003-4819-124-8-199604150-00002
Text Size: A A A

Objective: To determine whether growth hormone replacement in older men improves functional ability.

Design: Randomized, controlled, double-blind trial.

Setting: General community.

Patients: 52 healthy men older than 69 years of age with well-preserved functional ability but low baseline insulin-like growth factor 1 levels.

Intervention: Growth hormone (0.03 mg/kg of body weight) or placebo given three times a week for 6 months.

Measurements: Body composition, knee and hand grip muscle strength, systemic endurance, and cognitive function.

Results: The participants' mean age was 75.0 years (range, 70 to 85 years). At 6 months, lean mass had increased on average by 4.3% in the growth hormone group and had decreased by 0.1% in the placebo group, a difference of 4.4 percentage points (95% CI, 2.1 to 6.8 percentage points). Fat mass decreased by an average of 13.1% in the growth hormone group and by 0.3% in the placebo group, a difference of 12.8 percentage points (CI, 8.6 to 17.0 percentage points). No statistically or clinically significant differences were seen between the groups in knee or hand grip strength or in systemic endurance. The mean Trails B score in the growth hormone group improved by 8.5 seconds, whereas scores in the placebo group deteriorated by 5.0 seconds, a difference of 13.5 seconds (CI, 3.1 seconds to 23.9 seconds; P = 0.01) However, the growth hormone group's score on the Mini-Mental Status Examination deteriorated by 0.4, whereas the placebo group's score improved by 0.2, a difference of 0.6 (P = 0.11). The two treatment groups had almost identical scores on the Digit Symbol Substitution Test (P > 0.2). Twenty-six men in the growth hormone group had 48 incidents of side effects, and 26 placebo recipients had 14 incidents of side effects (P = 0.002). Dose reduction was required in 26% of the growth hormone recipients and in none of the placebo recipients (P < 0.001).

Conclusions: Physiologic doses of growth hormone given for 6 months to healthy older men with well-preserved functional abilities increased lean tissue mass and decreased fat mass. Although body composition improved with growth hormone use, functional ability did not improve. Side effects occurred frequently.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)